Dr. Alex Movshis prescribes semaglutide. That surprises some patients who come to Modal Pain Management NYC for knee arthritis or back pain. They expect injections, nerve blocks, maybe physical therapy. They do not expect their pain doctor to bring up a weight-loss medication.
For a specific group of patients it is one of the most useful things we can offer. This is a physician-supervised program at 369 Lexington Avenue, Floor 25, for people whose knee, hip or back pain is made worse by the weight their joints carry. It is not a general weight-loss clinic and not a med-spa service. The program is run by Dr. Movshis, who is board-certified in pain medicine and anesthesiology, and it sits inside the same pain treatment plan as the injections and the physical therapy.
Why weight changes knee, hip and back pain
The best-measured effect is mechanical. In older adults with knee osteoarthritis, every pound of weight lost took about four pounds of force off the knee with each step (Messier et al., 2005). Lose 20 pounds and that is roughly 80 pounds less load per step, repeated thousands of times a day. The 2019 American College of Rheumatology guideline strongly recommends weight loss for people with knee or hip osteoarthritis who are overweight, and notes that losing 5% or more of body weight is associated with meaningful improvement, with more benefit at 10% and 20% (Kolasinski et al., 2020). In the IDEA trial, adults with knee osteoarthritis who lost about 11% of their weight with diet plus exercise had lower IL-6, less pain and better function at 18 months than those who only exercised (Messier et al., 2013).
The spine is less clear-cut. Extra weight changes posture and load on the lower back, but the evidence that losing weight improves back pain is thinner than it is for the knee. For sciatica or a disc problem, weight loss is a supporting step, not the treatment.
The second mechanism is less certain. Visceral fat is metabolically active and releases inflammatory signals, including interleukin-6, tumor necrosis factor-alpha and leptin. That low-grade inflammation is one proposed reason obesity is linked to pain beyond the weight-bearing joints. In a survey of more than 30,000 US adults, for example, obesity was associated with higher rates of chronic (transformed) migraine (Bigal & Lipton, 2006). An association like that does not prove that losing weight will reduce the pain.
The cycle that keeps pain patients heavy
Pain limits movement. Less movement means fewer calories burned and more muscle loss, and weaker muscles make the joint less stable and more painful. Poor sleep from pain makes appetite harder to control. So patients get stuck: the pain is treated and partly better, but they still hurt too much to exercise enough to lose weight, or they crash-diet, cannot sustain it and regain it. A GLP-1 medication works on the weight side of that loop. As the weight comes off, the joints carry less load and exercise becomes possible in a way it was not before, which is where the longer-term gains come from.
How semaglutide and tirzepatide work
Semaglutide (Wegovy, Ozempic) is a GLP-1 receptor agonist. It mimics a hormone the gut releases after a meal. That hormone tells the brain you are full, slows how quickly the stomach empties and quiets what many patients call food noise, the constant background thinking about the next meal. Tirzepatide (Zepbound, Mounjaro) acts on both the GLP-1 and the GIP receptors.
What patients describe most often is that it is not willpower. They are simply less hungry, eat a normal portion and feel satisfied.
Which medication, and at what dose
GLP-1 prescribing here follows the published titration schedules. Prescriptions are usually for the brand-name medications. Compounded versions are used rarely, and come from 503A or 503B compounding pharmacies.
Semaglutide injection (Wegovy). A weekly shot under the skin of the abdomen or thigh, starting at 0.25 mg for four weeks and stepping up every four weeks to 0.5 mg, 1.0 mg, 1.7 mg and the 2.4 mg maintenance dose at week 17. If side effects are hard to tolerate, the next increase can wait, as the label allows. A higher-dose version, Wegovy HD at 7.2 mg a week, was approved by the FDA in March 2026 for people who need more effect than 2.4 mg gives them.
Semaglutide pill (Wegovy pill). Oral semaglutide, started at 1.5 mg a day and stepped up to a 25 mg maintenance dose. It only absorbs properly on an empty stomach: on waking, with a sip of water (no more than 4 ounces), then at least 30 minutes before food, drinks or other pills. For patients who take several morning medications, that rule matters more than they expect.
Tirzepatide injection (Zepbound). A weekly shot starting at 2.5 mg for four weeks, then 5 mg, then increases in 2.5 mg steps at least four weeks apart to a maintenance dose of 5, 10 or 15 mg, depending on response and tolerability.
What results to expect
These are averages from the main trials. Individual results vary a lot, and none of these numbers is a promise.
| Medication | Trial | Average weight loss | Placebo |
|---|---|---|---|
| Semaglutide 2.4 mg weekly | STEP 1, 68 weeks | 14.9% | 2.4% |
| Semaglutide 7.2 mg weekly | STEP UP, 72 weeks | 18.7% (15.6% on 2.4 mg) | 3.9% |
| Semaglutide 25 mg pill daily | OASIS 4, 64 weeks | 13.6% | 2.2% |
| Tirzepatide 5 / 10 / 15 mg weekly | SURMOUNT-1, 72 weeks | 15.0% / 19.5% / 20.9% | 3.1% |
Sources: Wilding 2021, Wharton 2025, STEP UP, Wharton 2025, OASIS 4, Jastreboff 2022. For someone who weighs 220 pounds, 15% is about 33 pounds.
For pain specifically, the trial to know is STEP 9. In people with obesity and knee osteoarthritis, semaglutide 2.4 mg lowered WOMAC knee pain scores by 41.7 points on a 100-point scale over 68 weeks, against 27.5 points with placebo, with weight loss of 13.7% against 3.2% (Bliddal et al., 2024). Note that the placebo group improved a lot too, which is common in pain trials and is one reason we measure your own pain and function at each visit rather than relying on the average.
Patients who have lost less than 5% of their body weight by week 20 are reassessed for a dose change or a different approach.
The first six months, month by month
Weeks 1 to 4. Most patients notice mild appetite suppression. Some feel nothing yet. Nausea is the most common side effect, usually mild and usually worst in the first few days after each dose increase. Smaller meals and avoiding greasy food help. Constipation is common enough that we plan for it from the start.
Months 2 and 3. The dose increases start to change appetite more clearly, and weight loss usually shows up on the scale. Some patients say their pain is slightly better, though it is early.
Months 4 to 6. Weight loss continues. This is when patients with knee arthritis often say they are moving and sleeping better, which fits the STEP 9 timeline.
After month 6. The rate slows. In STEP 1 the average weight curve had flattened by the end of the 68-week trial. What happens next depends on whether you stay on the medication, covered below.
Side effects, including the ones that matter to pain patients
Stomach side effects. Nausea is the big one. Across the STEP 1 to 3 trials it affected 43.9% of people on semaglutide 2.4 mg against 16.1% on placebo. Most stomach side effects were mild to moderate, temporary and clustered around dose increases, and 4.3% stopped the drug because of them (Wharton et al., 2022). Constipation and diarrhea both occur, sometimes in the same person at different times. Eating slowly, avoiding large meals and drinking enough water help more than anything else.
Skin sensations at the higher dose. In STEP UP, dysaesthesia, meaning unusual skin sensations such as tingling or sensitivity, was reported by 22.9% of people on 7.2 mg, against 6.0% on 2.4 mg and 0.5% on placebo (Wharton et al., 2025). For patients who already have nerve pain, that is worth knowing before moving to the higher dose, so a new symptom is not mistaken for their neuropathy getting worse.
Less common but serious. Gallstones, acute pancreatitis and kidney injury from dehydration. Gallbladder problems are more likely with rapid weight loss. Severe or persistent belly pain, especially pain that goes through to the back, needs an urgent medical evaluation. If you have severe pain, vomiting you cannot stop, or signs of serious dehydration such as fainting or very little urine, call 911 or go to the nearest emergency room.
Anesthesia and sedation. Because these drugs slow stomach emptying, the labels warn about the risk of inhaling stomach contents during general anesthesia or deep sedation. Tell anyone doing a procedure under sedation that you take one.
For patients who are struggling to keep fluids down during dose increases, we offer a GLP-1 Support IV with fluids and nutrients. No trial has shown that an IV reduces GLP-1 side effects, and slow dose escalation remains the step with real evidence behind it.
When a GLP-1 is not safe
These medications are not used in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), which reflects the boxed warning based on thyroid C-cell tumors in rodents. They are not used in people with a known hypersensitivity to the drug. They are used with caution, or not at all, in people with a history of pancreatitis, severe gastroparesis or active gallbladder disease.
They are not used in pregnancy, and the Wegovy label advises stopping semaglutide at least two months before a planned pregnancy. Tirzepatide can make birth control pills less reliable for four weeks after starting and after each dose increase, so a backup method is advised during those windows.
Who this program is for
The labels cover adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Chronic pain on its own is not one of the listed conditions, and insurers decide what qualifies for coverage. Within that, the program is a good fit for:
- Knee, hip or spine pain where the exam or imaging points to weight-driven joint loading, including knee osteoarthritis and facet joint pain.
- Patients whose surgeon wants them at a lower weight before a joint replacement.
- Patients having procedures such as radiofrequency ablation or epidural steroid injections for back or joint pain, where weight is still part of the problem.
- Chronic widespread pain or fibromyalgia with obesity, with the understanding that the evidence for pain benefit is weaker here than for the knee.
- Chronic migraine with excess weight, given the association between obesity and chronic migraine.
- Metabolic syndrome or insulin resistance alongside a chronic pain condition.
It is not the right program for cosmetic weight loss without a pain indication, for anyone who wants a GLP-1 prescription without follow-up, or for anyone with the contraindications above.
What the first visit includes
The first visit runs 45 to 60 minutes:
- A pain history focused on mechanical contributors and the conservative care you have already tried.
- Vital signs, BMI, waist-to-hip ratio and a musculoskeletal exam.
- A medication review, looking for interactions. Delayed stomach emptying can change how oral medications are absorbed.
- Baseline labs: a chemistry panel with kidney and liver function, hemoglobin A1c, lipids, TSH and lipase.
- A written plan naming the medication, the titration schedule, the follow-up schedule and the targets for both weight and pain.
Medication is only one part. The plan usually includes physical therapy with our in-house team on the same floor, because protecting muscle during weight loss takes resistance exercise and enough protein, and because the strength you build is what keeps the joint comfortable once the weight is off.
Follow-up, and what happens when you stop
During titration, patients are seen every 4 to 8 weeks, then quarterly on a maintenance dose. Each visit covers weight, blood pressure, side effects and a fresh look at the pain problem that justified the prescription.
The question patients ask most is whether the weight comes back if they stop. For most people a large share does. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year (Wilding et al., 2022). So the plan is decided up front: long-term treatment at the lowest dose that holds the result, or a planned taper with close follow-up while the pain treatment continues.
Insurance and cost
GLP-1 medications for weight loss are inconsistently covered by commercial plans. Coverage usually requires a documented BMI threshold (30, or 27 with a weight-related condition) and often prior authorization, and some plans exclude weight-loss drugs entirely. We check your coverage and talk through costs by phone before the visit, so you are not surprised by a bill. Modal Pain Management NYC accepts most commercial PPO plans, including Aetna, Anthem Blue Cross Blue Shield, Cigna, Empire Blue Cross Blue Shield, the Empire Plan, Oscar, Oxford, UMR and UnitedHealthcare. It does not accept Medicare, Medicaid, HMO plans, or workers’ compensation. Patients with those plans should check their plan directory for providers who accept their plan.
For self-pay patients, current cash-price options for these medications are discussed at the consultation. See the insurance and billing page for how verification works.
What this program does not offer
- Weight-loss treatment without a pain indication.
- Mobile or unsupervised GLP-1 dispensing.
- HCG injections, lipotropic shots or drips sold as fat burners, or unregulated peptides.
- Any prescription without baseline labs and physician follow-up.
The program runs to the same standards as the rest of the practice. See the credentials and verification page for Dr. Movshis’s training and board certification.
References
- Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026–32. doi:10.1002/art.21139 · PubMed
- Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263–73. doi:10.1001/jama.2013.277669 · PubMed
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220–233. doi:10.1002/art.41142 · PubMed
- Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573–1583. doi:10.1056/NEJMoa2403664 · PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PubMed
- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–963. doi:10.1016/S2213-8587(25)00226-8 · PubMed
- Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969 · PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 · PubMed
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725 · PubMed
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. doi:10.1111/dom.14551 · PubMed
- Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67(2):252–7. doi:10.1212/01.wnl.0000225052.35019.f9 · PubMed
- US Food and Drug Administration. FDA approves fourth product under National Priority Voucher Program, higher dose semaglutide. March 19, 2026. fda.gov